GENE ONLINE|News &
Opinion
Blog

Autoimmune Disease
Netherlands-based Argenx Raises $1.1 Billion in Global Offering Following Success in Clinical Trials
2023-07-23
Merck Buys Prometheus For $10.8 Billion, Lands Promising Autoimmune Asset
2023-04-17
Vera Therapeutics Eyes Phase 3 For Kidney Disease Candidate Following Positive Data
2023-01-04
GeneOnline’s Pick: Top 10 M&A Deals in 2022
2022-12-28
Vallon and GRI Bio Strike a Merger Deal, Joining Forces for Innovative NKT Cell Regulators
2022-12-14
Japan Approves AstraZeneca’s Complement Inhibitor For Rare Muscle Disorder
2022-08-26
Takeda Announces Positive Topline From Pivotal Trial For Autoimmune Disease
2022-07-25
How Single Cell Sequencing is Advancing Biomedical Research
2022-07-15
New Mitochondrial Response Pathway May Advance Treatments for Inflammatory Diseases
2022-07-14
AbbVie & Cugene Join Forces to Tackle Autoimmune Diseases
2022-05-17
GSK’s Benlysta Bags Approval for Lupus Nephritis Treatment in China
2022-02-14
Sanofi’ Enjaymo Wins FDA Approval for Rare Autoimmune Anemia
2022-02-07
With New Funding, ACELYRIN Licenses First Therapeutic and Leaps into Late-Stage Trials for Autoimmune Diseases
2021-11-17
Mozart Therapeutics Makes Play with $55 Million Series A to Capitalize on Novel Tregs Pathway
2021-10-27
GentiBio Bags $157 Million in Series A to Fund Development of Treg Cell Therapies
2021-08-11
1 2
LATEST
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
2024-04-22
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
2024-04-22
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
2024-04-19
The Legal Battlefield of Weight-Loss Drugs: Eli Lilly and Novo Nordisk on the Defensive
2024-04-18
Pharmacogenomics in Asia-Pacific: Nalagenetics CEO Levana Sani Offers Insights and Strategies
2024-04-17
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
Scroll to Top